NZ628458A - Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis - Google Patents

Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis

Info

Publication number
NZ628458A
NZ628458A NZ628458A NZ62845813A NZ628458A NZ 628458 A NZ628458 A NZ 628458A NZ 628458 A NZ628458 A NZ 628458A NZ 62845813 A NZ62845813 A NZ 62845813A NZ 628458 A NZ628458 A NZ 628458A
Authority
NZ
New Zealand
Prior art keywords
combination
genes
prognosing
expression level
pulmonary fibrosis
Prior art date
Application number
NZ628458A
Other languages
English (en)
Inventor
Joseph R Arron
Guiquan Jia
Alexander R Abbas
Sanjay Chandriani
Nicholas J I Lewin-Koh
Daryle Depianto
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NZ628458A publication Critical patent/NZ628458A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
NZ628458A 2012-03-27 2013-03-14 Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis NZ628458A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261616394P 2012-03-27 2012-03-27
US201261707411P 2012-09-28 2012-09-28
PCT/US2013/031178 WO2013148232A1 (en) 2012-03-27 2013-03-14 Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis

Publications (1)

Publication Number Publication Date
NZ628458A true NZ628458A (en) 2016-11-25

Family

ID=49261043

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ628458A NZ628458A (en) 2012-03-27 2013-03-14 Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis

Country Status (16)

Country Link
US (2) US20160230226A1 (cg-RX-API-DMAC7.html)
EP (2) EP2831280B1 (cg-RX-API-DMAC7.html)
JP (1) JP6404208B2 (cg-RX-API-DMAC7.html)
KR (1) KR102197524B1 (cg-RX-API-DMAC7.html)
CN (2) CN107099581B (cg-RX-API-DMAC7.html)
AR (1) AR090339A1 (cg-RX-API-DMAC7.html)
AU (2) AU2013240344A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014023348A2 (cg-RX-API-DMAC7.html)
CA (1) CA2864884A1 (cg-RX-API-DMAC7.html)
HK (1) HK1206796A1 (cg-RX-API-DMAC7.html)
IL (1) IL256396A (cg-RX-API-DMAC7.html)
MX (2) MX370486B (cg-RX-API-DMAC7.html)
NZ (1) NZ628458A (cg-RX-API-DMAC7.html)
RU (1) RU2014139546A (cg-RX-API-DMAC7.html)
SG (2) SG11201405830VA (cg-RX-API-DMAC7.html)
WO (1) WO2013148232A1 (cg-RX-API-DMAC7.html)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
CN102459636B (zh) 2009-05-07 2016-08-17 威拉赛特公司 用于诊断甲状腺病症的方法和组合物
US9347954B2 (en) 2011-09-06 2016-05-24 Shino-Test Corporation Antibody capable of binding to specific region of periostin, and method of measuring periostin using the same
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
CA3172586C (en) 2013-07-31 2025-10-14 Avalyn Pharma Inc. IMATINIB AEROSOL COMPOUNDS AND RELATED USES
BR112016008694A2 (pt) * 2013-10-23 2017-10-03 Genentech Inc Métodos de previsão da reação de pacientes com asma, de previsão da capacidade de reação de pacientes com asma, de identificação de pacientes com asma, de tratamento de pacientes portadores de asma e de tratamento de asma, uso de um kit e kit
JP6312054B2 (ja) * 2013-11-06 2018-04-18 学校法人日本大学 間質性肺炎のバイオマーカー
US20160256485A1 (en) * 2013-11-14 2016-09-08 Proterris, Inc. Treatment or prevention of pulmonary conditions with carbon monoxide
CA2934662C (en) 2013-12-20 2024-02-20 President And Fellows Of Harvard College Low shear microfluidic devices and methods of use and manufacturing thereof
WO2015120257A2 (en) * 2014-02-06 2015-08-13 The Brigham And Women's Hospital, Inc. Uses of gli1 in detecting tissue fibrosis
TW201618795A (zh) 2014-04-15 2016-06-01 波泰里斯股份有限公司 用以改良器官功能及延長器官移植物壽命之系統及方法
WO2015164716A1 (en) * 2014-04-25 2015-10-29 Brown University Methods for the diagnosis and treatment of pulmonary fibrosis in subjects with hermansky pudlak syndrome
US9913819B2 (en) 2014-06-12 2018-03-13 Yale University Methods of treating or preventing fibrotic lung diseases
EP2957634A1 (en) 2014-06-20 2015-12-23 Consejo Superior De Investigaciones Científicas Compounds for prevention and/or treatment of fibrotic diseases
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
JP7356788B2 (ja) 2014-11-05 2023-10-05 ベラサイト インコーポレイテッド 機械学習および高次元転写データを使用して経気管支生検における特発性肺線維症を診断するシステムおよび方法
CN104792998B (zh) * 2015-03-09 2016-06-08 中国人民解放军第四军医大学 Loxl2抗原用于制备甲状腺癌预示、侵袭、转移试剂盒的应用
CN106290892A (zh) * 2015-06-26 2017-01-04 上海市肿瘤研究所 Cthrc1在肝硬化诊断和治疗中的应用
WO2017044752A1 (en) * 2015-09-10 2017-03-16 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Anti-fibrotic effect of cd70
HUE065418T2 (hu) * 2015-10-27 2024-05-28 Univ Taipei Medical Indolin származékok fibrózisos betegségek kezelésére és/vagy megelõzésére
CN105400870B (zh) * 2015-11-11 2018-09-25 南方医科大学 CD1c在菌阴肺结核诊断中的应用
MX2018006269A (es) * 2015-11-23 2018-09-05 Merck Patent Gmbh Anticuerpo anti-alfa-v-integrina para el tratamiento de fibrosis y/o trastornos fibroticos.
JP7034914B2 (ja) 2015-11-23 2022-03-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 線維症および／または線維性疾患の治療のための抗α－ｖインテグリン抗体
JP2019522638A (ja) * 2016-05-27 2019-08-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ニンテダニブ及びピルフェニドンによる治療開始を判定するためのｅｃｍバイオマーカーの使用
CN106319058B (zh) * 2016-08-31 2019-09-10 汪道文 一种检测特发性肺纤维化致病基因的dna文库及其应用
AU2017324949B2 (en) * 2016-09-07 2024-05-23 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
WO2018081236A1 (en) * 2016-10-28 2018-05-03 Cedars-Sinai Medical Center Method of predicting progression of idiopathic pulmonary fibrosis and monitoring of therapeutic efficacy
US20200017913A1 (en) * 2017-03-02 2020-01-16 President And Fellows Of Harvard College Methods and systems for predicting treatment responses in subjects
IT201700026858A1 (it) * 2017-03-10 2018-09-10 Univ Degli Studi Padova Uso di inibitori delle serin proteasi, in particolare di serpinb3
US20190127456A1 (en) * 2017-10-31 2019-05-02 Fibrogen, Inc. Methods of treating idiopathic pulmonary fibrosis
CN108931645A (zh) * 2018-07-26 2018-12-04 北京大学第医院 一种hcv清除后肝纤维化评估系统及评估方法
EP3849580A4 (en) 2018-09-10 2022-06-15 Lung Therapeutics, Inc. Modified peptide fragments of cav-1 protein and the use thereof in the treatment of fibrosis
WO2020090683A1 (ja) * 2018-10-29 2020-05-07 国立大学法人東京医科歯科大学 間質性肺炎患者の呼吸機能の低下リスクに関する情報を取得する方法及びその利用
WO2020146887A1 (en) * 2019-01-11 2020-07-16 University Of Virginia Patent Foundation Compositions and methods for predicting lung function decline in idiopathic pulmonary fibrosis
WO2022026922A2 (en) * 2020-07-31 2022-02-03 Genentech, Inc. Methods for treating exacerbations of inflammatory respiratory diseases
CA3209638A1 (en) 2021-02-25 2022-09-01 Lung Therapeutics, Inc. Biomarkers for the treatment of interstitial lung disease
ES2957479B2 (es) * 2022-06-07 2025-07-28 Baigene S L Metodo de obtencion de datos utiles para la prediccion del riesgo de un sujeto de sufrir fibrosis
PE20251639A1 (es) 2022-06-17 2025-06-24 Apogee Biologics Inc Anticuerpos que se unen a interleuquina 13 y metodos de uso
CN115925920B (zh) * 2022-08-04 2023-07-25 瑞因细胞工程科技(广州)有限公司 一种基因增强型免疫细胞治疗肝硬化的方法
WO2024105446A1 (en) * 2022-11-14 2024-05-23 Alentis Therapeutics Ag Biomarkers for fibrosis treatment using anti-claudin-1 antibodies
CN117747093B (zh) * 2024-02-20 2024-06-07 神州医疗科技股份有限公司 一种特发性肺纤维化诊断模型的构建方法及诊断系统
CN119162300A (zh) * 2024-09-12 2024-12-20 中国人民解放军陆军军医大学第一附属医院 用于预测肺纤维化程度及预后情况的标志物、模型及应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
JPH06105020B2 (ja) 1992-06-09 1994-12-21 ホッペ・アーゲー ラッチ及びロックアップシステム
AU5632296A (en) 1995-04-27 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
AR045614A1 (es) * 2003-09-10 2005-11-02 Hoffmann La Roche Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos
DK2805728T3 (da) * 2003-12-23 2020-04-20 Genentech Inc Hidtil ukendte anti-IL13-antistoffer og anvendelser deraf
US20080044420A1 (en) 2005-05-11 2008-02-21 Heavner George A Anti-IL-13 antibodies, compositions, methods and uses
PL1942939T5 (pl) 2005-09-30 2021-10-11 Medimmune Limited Kompozycja przeciwciała interleukiny-13
EP1957530A2 (en) 2005-10-21 2008-08-20 Novartis AG Human antibodies against il13 and therapeutic uses
BRPI0706575B8 (pt) * 2006-01-13 2021-05-25 Univ Indiana Res & Tech Corp uso colágeno de tipo v ou um componente antigênico do mesmo, e, método para identificar um paciente em espera de transplante de pulmão para um risco aumentado de rejeição de tecido de órgão transplantado.
TWI395754B (zh) * 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
US20100074886A1 (en) * 2006-10-05 2010-03-25 Anuk Das Ccr2 antagonists for treatment of fibrosis
WO2008083695A1 (de) 2006-12-20 2008-07-17 Patent-Treuhand-Gesellschaft für elektrische Glühlampen mbH Vorrichtung und verfahren zur messung der intensität des lichtes einer ersten gruppe von lichtquellen einer beleuchtungseinheit
CN101977935A (zh) * 2007-04-23 2011-02-16 惠氏公司 用于治疗和监测il-13相关病症的方法和组合物
EP2050764A1 (en) * 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
CA2705486C (en) * 2007-11-19 2019-04-02 Celera Corporation Lung cancer markers and uses thereof
MX348362B (es) * 2008-03-31 2017-06-07 Genentech Inc * Composiciones y metodos para tratar y diagnosticar asma.
WO2010028274A1 (en) * 2008-09-05 2010-03-11 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Marker panels for idiopathic pulmonary fibrosis diagnosis and evaluation
MX2011005541A (es) * 2008-11-26 2011-09-21 Glaxo Group Ltd Ligandos que se enlazan a il-13.
US8911960B2 (en) * 2009-06-01 2014-12-16 Case Western Reserve University Method for identifying idiopathic pneumonia progression by measuring the level of mannose-binding protein C
TWI666447B (zh) * 2010-12-16 2019-07-21 建南德克公司 關於ｔｈ２抑制作用之診斷及治療

Also Published As

Publication number Publication date
MX2014011503A (es) 2014-12-05
AU2013240344A1 (en) 2014-09-18
KR102197524B1 (ko) 2020-12-31
HK1206796A1 (en) 2016-01-15
IL256396A (en) 2018-02-28
CA2864884A1 (en) 2013-10-03
EP2831280A4 (en) 2016-02-24
CN107099581B (zh) 2021-07-13
EP3725892A1 (en) 2020-10-21
US20190062836A1 (en) 2019-02-28
BR112014023348A2 (pt) 2019-03-19
CN107099581A (zh) 2017-08-29
SG10201702842SA (en) 2017-06-29
RU2014139546A (ru) 2016-05-20
US20160230226A1 (en) 2016-08-11
JP6404208B2 (ja) 2018-10-10
KR20140143196A (ko) 2014-12-15
MX370486B (es) 2019-12-16
MX2019015159A (es) 2020-02-19
CN104334744A (zh) 2015-02-04
EP2831280B1 (en) 2020-04-15
EP2831280A1 (en) 2015-02-04
JP2015522246A (ja) 2015-08-06
AR090339A1 (es) 2014-11-05
AU2018250393A1 (en) 2018-11-08
SG11201405830VA (en) 2014-10-30
WO2013148232A1 (en) 2013-10-03

Similar Documents

Publication Publication Date Title
NZ628458A (en) Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis
EP4219744A3 (en) Methods of preparing nucleic acids for sequencing
MY188348A (en) Single-molecule sequencing of plasma dna
EA201590488A1 (ru) Способы модификации клеток-хозяев
MX360479B (es) Anticuerpos contra microbioma, factores de estres y marcadores de mastocitos como marcadores de diagnostico para ibs.
CA2867508C (en) Immunofluorescence and fluorescent-based nucleic acid analysis on a single sample
MX2014001383A (es) Colageno 7 y metodos relacionados.
GB2519906A (en) Methods and systems for detecting biological components
UA115321C2 (uk) Спосіб та комплект для аналізу ahasl генів у рослин
MX375586B (es) Metodo para diagnosticar cancer colorrectal a partir de una muestra de heces humanas por pcr cuantitativa, cebadores y equipo.
MX2015015784A (es) Metodos para diagnosticar y tratar enfermedad inflamatoria de intestino.
MX353186B (es) Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide.
IN2014DN07533A (cg-RX-API-DMAC7.html)
EA201290527A1 (ru) Способы выделения мононуклеарных клеток, которые включают субпопуляцию мезенхимальных клеток-предшественников, и сосудистых клеток, которые включают субпопуляцию эндотелиальных клеток-предшественников, из пуповинной ткани
WO2010115745A3 (en) Biomarkers, methods and kits for the diagnosis of rheumatoid arthritis
EA201590773A1 (ru) Способ диагностики для прогнозирования ответа на ингибитор фактора некроза опухоли альфа (tnf альфа)
MD20130098A2 (ro) Test pentru determinarea lizil oxidazei-2 şi metode de utilizare a acestuia
PH12015501687A1 (en) Novel binding proteins from pcsk9
WO2015112948A3 (en) Methods for determining a nucleotide sequence
EA201290107A1 (ru) Способ определения пациента как восприимчивого или не восприимчивого к иммунотерапии
WO2011085134A8 (en) Methods and compositions for the diagnosis, prognosis and treatment of cancer
MX368486B (es) Plantas cucurbitaceas androceas, metodos de obtencion y usos de dichas plantas cucurbitaceas.
GB2552271A (en) A method for diagnosing lung cancer
MX2016017136A (es) Composiciones y metodos para detectar pegivirus 2 de humano (hpgv-2).
MX2018002947A (es) Composiciones, dispositivos, y métodos de pruebas de sensibilidad a la osteoartritis.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAR 2018 BY AJ PARK

Effective date: 20170612

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAR 2019 BY THOMSON REUTERS

Effective date: 20180217

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAR 2020 BY THOMSON REUTERS

Effective date: 20190216

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAR 2021 BY THOMSON REUTERS

Effective date: 20200205

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAR 2022 BY THOMSON REUTERS

Effective date: 20210206

LAPS Patent lapsed